The deal was Novo Nordisk’s bid to grab back market share from the cheaper, knockoff versions that Hims & Hers and other ...

Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for the first six months of ...

Shares in the $247 bln obesity drugmaker fell over 20% after it said sales would grow more slowly than expected. Competition ...

Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective ...

The maker of GLP-1 drugs Ozempic and Wegovy cut sales grown from 13%-21% down to 8%-14% for the year. That's about half, on the higher end, of the 26% growth seen in 2024. Outgoing CEO Lars Jøregensen ...

Ltd. (Novo Nordisk) today announced the successful completion of the Affordability Project in Thailand as part of its ongoing commitment to drive change in diabetes in the country. This transformative ...

President Trump escalated efforts to reduce drug prices in the US on Thursday, releasing letters sent to 17 pharmaceutical ...

GLP-1 receptor agonists are an important drug class and have become widely popular due to their effectiveness in weight ...

What Happened? On April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of“a bundled offering of Novo Nordisk's FDA-approved Wegovy on the Hims & ...

Global stocks weakened on Friday after Donald Trump hit dozens of countries with tariffs, as the US president pushed ahead ...

Switzerland’s new rate is even higher than the 31 per cent outlined on Trump’s “liberation day” in April. It also makes the ...

During the second quarter of 2025, the Company repurchased shares of its common stock and recorded the cost of the shares, or $1.070 billion, as Treasury Stock. As of June 30, 2025, $2.814 billion ...